Kristan Staudenmayer

Back to Profile

Publication Details

  • Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications.

    Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS. Ann Intern Med. 2011; 154 (8): 529-40

    Recombinant factor VIIa (rFVIIa), a hemostatic agent approved for hemophilia, is increasingly used for off-label indications.

    PubMedID: 21502651

Stanford Medicine Resources:

Footer Links: